{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-058140","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-05-18T12:15:16+00:00","discovered_at":"2026-05-18T12:20:00.354622+00:00","generated_at":"2026-05-18T12:21:49.339373+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead","bullets":["Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.","GX-03 is a topical therapy in Phase 2 trial for moderate-to-severe atopic dermatitis (eczema).","Hahn cited personal family experience with atopic dermatitis as motivation for his role.","CEO Bradley Burnam highlighted Hahn's scientific rigor, regulatory expertise, and patient focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058140","json":"https://secwatch.observer/filing/0001213900-26-058140.json","markdown":"https://secwatch.observer/filing/0001213900-26-058140.md","text":"https://secwatch.observer/filing/0001213900-26-058140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/0001213900-26-058140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/ea0291223-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T12:21:49.339373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}